• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lundquist Investigator Dr. Ashraf Ibrahim Is the Lead Author in the Landmark Study on Pioneering Oral Fungal Infection Treatment Showing Promise in Preclinical Trials

By: The Lundquist Institute for Biomedical Innovation via GlobeNewswire
April 30, 2024 at 08:00 AM EDT

Torrance, California, April 30, 2024 (GLOBE NEWSWIRE) -- A novel oral amphotericin B (MAT2203) developed by Matinas BioPharma for treatment of invasive mucormycosis (IM) and other deadly invasive fungal infections, has demonstrated encouraging results in a series of preclinical studies. The groundbreaking research, led by Lundquist Institute (TLI) Investigator Ashraf Ibrahim, PhD, has been published in the journal Antimicrobial Agents and Chemotherapy.

The studies focused on MAT2203, an oral lipid nanocrystal formulation of amphotericin B, which has previously demonstrated safety and effectiveness in the clinical treatment of various fungal infections. The research aimed to evaluate the efficacy of MAT2203 in comparison to the current standard treatment, liposomal amphotericin B (LAMB), in a neutropenic mouse model. This model mimics the human condition of IM caused by two strains of fungus, Rhizopus arrhizus var. delemar and Mucor circinelloides f. jenssenii DI15-131.

Results indicated that a daily dose of 15 mg/kg of MAT2203 was as effective as 10 mg/kg of LAMB in extending the median survival time and improving overall survival rates. Furthermore, while both treatments significantly reduced the fungal burden in the lungs and brains of infected mice, LAMB showed a more pronounced effect in reducing tissue fungal load compared to MAT2203 when dealing with R. delemar infections.

Dr. Ibrahim commented on the findings, stating, "The promising outcomes of MAT2203 in this study represent a significant step towards a less invasive and safer treatment approach to combating invasive mucormycosis since unlike LAMB which is given intravenously, MAT2203 is administered orally and can be administered long-term without any of the significant toxicities associated with LAMB treatment. It's a testament to the potential of innovative drug delivery systems like lipid nanocrystals in transforming how we treat infectious diseases."

A higher dosage of MAT2203 (45 mg/kg) did not show added benefits and was less tolerated by the mice, highlighting the importance of dosing in the development of this treatment.

These findings support the continued research and development of MAT2203 as a novel oral treatment option for patients suffering from mucormycosis, potentially offering a safer, more effective, and convenient alternative to current therapies.

Attachment

  • Dr. Ashraf Ibrahim - Lundqist Investigator

Max Benavidez
The Lundquist Institute for Biomedical Innovation
310-200-2682
max.benavidez@lundquist.org

More News

View More
Amazon Stock Rally Hits New Highs: Buy Into Earnings?
July 22, 2025
Via MarketBeat
Tickers AMZN GOOGL META
Forget the Hype—TSMC Is the AI Stock That Actually Delivers
July 22, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers AAPL NVDA TSM
Why Lucid’s 36% Rally on Uber Deal Could Be a Game-Changer
July 22, 2025
Via MarketBeat
Topics Electric Vehicles
Tickers GOOG LCID TSLA UBER
Block Levels Up: What S&P 500 Inclusion Means for Investors
July 22, 2025
Via MarketBeat
Topics ETFs Stocks
Tickers XYZ
Steel Dynamics Stock Steady on Long-Term Prospects
July 22, 2025
Via MarketBeat
Topics World Trade
Tickers CLF STLD X
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap